Molecular Partners (Switzerland) Analysis
| MOLN Stock | CHF 3.11 0.12 4.01% |
Molecular Partners AG is fairly valued with Real Value of 3.07 and Hype Value of 2.99. The main objective of Molecular Partners stock analysis is to determine its intrinsic value, which is an estimate of what Molecular Partners AG is worth, separate from its market price. There are two main types of Molecular Partners' stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Molecular Partners' performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Molecular Partners' stock to identify patterns and trends that may indicate its future price movements.
The Molecular Partners stock is traded in Switzerland on SIX Swiss Exchange, with the market opening at 09:00:00 and closing at 17:30:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in Switzerland. Molecular Partners is usually not traded on Good Friday, Berchtoldstag, Easter Monday, International Workers ' Day, Ascension Day ( 2025 ), Whitmonday ( 2025 ), National Day, Christmas Eve ( 2025 ), Christmas Day, St . Stephen 's Day, New Year 's Eve ( 2025 ), New Year 's Day. Molecular Stock trading window is adjusted to Europe/Zurich timezone.
Molecular |
Molecular Stock Analysis Notes
About 14.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.89. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Molecular Partners had not issued any dividends in recent years. Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland. MOLECULAR PARTNERS operates under Biotechnology classification in Switzerland and is traded on Switzerland Exchange. It employs 163 people. To find out more about Molecular Partners AG contact Patrick Amstutz at (41) 44 755 77 07 or learn more at www.molecularpartners.com.Molecular Partners Investment Alerts
| Molecular Partners generated a negative expected return over the last 90 days | |
| Molecular Partners has high historical volatility and very poor performance | |
| The company reported the revenue of 9.33 M. Net Loss for the year was (63.78 M) with loss before overhead, payroll, taxes, and interest of (45.96 M). | |
| Molecular Partners AG has accumulated about 267.13 M in cash with (90.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 14.0% of the company outstanding shares are owned by corporate insiders |
Molecular Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 215.91 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Molecular Partners's market, we take the total number of its shares issued and multiply it by Molecular Partners's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Molecular Profitablity
Molecular Partners' profitability indicators refer to fundamental financial ratios that showcase Molecular Partners' ability to generate income relative to its revenue or operating costs. If, let's say, Molecular Partners is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Molecular Partners' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Molecular Partners' profitability requires more research than a typical breakdown of Molecular Partners' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of 0.62 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.61 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.61. Technical Drivers
As of the 21st of July, Molecular Partners secures the Risk Adjusted Performance of (0.02), standard deviation of 3.02, and Mean Deviation of 2.33. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Molecular Partners, as well as the relationship between them. Please verify Molecular Partners information ratio, maximum drawdown, potential upside, as well as the relationship between the treynor ratio and value at risk to decide if Molecular Partners AG is priced some-what accurately, providing market reflects its recent price of 3.11 per share.Molecular Partners Price Movement Analysis
The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. The Simple Moving Average indicator is calculated by adding the closing price of Molecular Partners for a given number of time periods and then dividing this total by the number of time periods. It is used to smooth out Molecular Partners short-term fluctuations and highlight longer-term trends or cycles.
Molecular Partners Outstanding Bonds
Molecular Partners issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Molecular Partners uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Molecular bonds can be classified according to their maturity, which is the date when Molecular Partners AG has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Molecular Partners Predictive Daily Indicators
Molecular Partners intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Molecular Partners stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 1745.57 | |||
| Daily Balance Of Power | 0.5714 | |||
| Rate Of Daily Change | 1.04 | |||
| Day Median Price | 3.01 | |||
| Day Typical Price | 3.04 | |||
| Price Action Indicator | 0.16 | |||
| Period Momentum Indicator | 0.12 |
Molecular Partners Forecast Models
Molecular Partners' time-series forecasting models are one of many Molecular Partners' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Molecular Partners' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Molecular Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Molecular Partners prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Molecular shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Molecular Partners. By using and applying Molecular Stock analysis, traders can create a robust methodology for identifying Molecular entry and exit points for their positions.
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland. MOLECULAR PARTNERS operates under Biotechnology classification in Switzerland and is traded on Switzerland Exchange. It employs 163 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Molecular Partners to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Correlation Analysis Now
Correlation AnalysisReduce portfolio risk simply by holding instruments which are not perfectly correlated |
| All Next | Launch Module |
Additional Tools for Molecular Stock Analysis
When running Molecular Partners' price analysis, check to measure Molecular Partners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Molecular Partners is operating at the current time. Most of Molecular Partners' value examination focuses on studying past and present price action to predict the probability of Molecular Partners' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Molecular Partners' price. Additionally, you may evaluate how the addition of Molecular Partners to your portfolios can decrease your overall portfolio volatility.